What is the definition of Undifferentiated Pleomorphic Sarcoma?

Undifferentiated pleomorphic sarcoma (UPS), also known as malignant fibrous histiocytoma, is a rare, aggressive soft tissue or bone cancer that usually occurs in the arms or legs in the sixth or seventh decade of life.

What are the symptoms for Undifferentiated Pleomorphic Sarcoma?

Symptoms of undifferentiated pleomorphic sarcoma may include the presence of a mostly painless, rapidly enlarging nodule in the lower extremities (especially the thigh), upper arms, head and neck, retroperitoneum, viscera, distal or proximal femur (upper leg), proximal tibia (lower leg), or humerus (upper arm). Additional symptoms of undifferentiated pleomorphic sarcoma may include pain, swelling, malaise, lack of appetite, constipation, fever, and weight loss.

What are the current treatments for Undifferentiated Pleomorphic Sarcoma?

Treatment for undifferentiated pleomorphic sarcoma depends on the location but may include surgery, radiation therapy, chemotherapy (ifosfamide, trabectedin, dacarbazine, and pazopanib), targeted therapy, and immunotherapy.
  • Condition: Maxillofacial and Paranasal Sinus Skull Base Malignant Tumor
  • Journal: Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • Treatment Used: Surgical Removal and Free Flap Repair
  • Number of Patients: 9
  • Published —
The study researched the outcomes of resection and free flap repair of recurrent maxillofacial and paranasal sinus skull base malignant tumor.
  • Condition: Primary Head and Neck Adult Sarcoma (HNS)
  • Journal: International journal of radiation oncology, biology, physics
  • Treatment Used: Surgery, Radiotherapy, Chemoradiotherapy (CRT), and Chemotherapy
  • Number of Patients: 21228
  • Published —
This review of the literature identified the best treatment for adult patients with primary head and neck sarcoma (HNS).
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Genetic, Drug
  • Participants: 48
  • Start Date: June 22, 2020
Allogeneic Natural Killer T-Cells Expressing CD19 Specific Chimeric Antigen Receptor and Interleukin-15 in Relapsed or Refractory B-Cell Malignancies
Clinical Trial
  • Status: Active, not recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Biological, Other
  • Participants: 140
  • Start Date: February 2, 2015
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab